Molecular Imaging and Biology

, Volume 11, Issue 3, pp 159–166

Biodistributions of 177Lu- and 111In-Labeled 7E11 Antibodies to Prostate-Specific Membrane Antigen in Xenograft Model of Prostate Cancer and Potential Use of 111In-7E11 as a Pre-therapeutic Agent for 177Lu-7E11 Radioimmunotherapy

  • Mei-Hsiu Pan
  • Dong-Wei Gao
  • Jinjin Feng
  • Jiang He
  • Youngho Seo
  • John Tedesco
  • John G. Wolodzko
  • Bruce H. Hasegawa
  • Benjamin L. Franc
Research Article

Abstract

Introduction

Prostate-specific membrane antigen is a transmembrane glycoprotein highly expressed in many prostate cancers and can be targeted with radiolabeled antibodies for diagnosis and treatment of this disease. To serve as a radioimmunotherapeutic agent, a kinetically inert conjugate is desired to maximize tumor uptake and tumor radiation dose with minimal nonspecific exposure to bone marrow and other major organs.

Materials and Methods

In this study, we assessed the pharmacokinetics and biodistribution of the 7E11 monoclonal antibody (MAb) radiolabeled with the lutetium-177 (177Lu)–tetraazacyclododecanetetraacetic acid conjugate system (177Lu-7E11) versus those of the 7E11 MAb radiolabeled with the indium-111 (111In)/glycyl-tyrosyl-(N,-diethylenetriaminepentaacetic acid)/lysine hydrochloride conjugate system (111In-7E11, also known as ProstaScint®) to determine the feasibility of using 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy. Pharmacokinetic and biodistribution studies of 177Lu-7E11 in lymph node cancer of the prostate (LNCaP) xenograft mice were performed at 2, 8, 12, 24, 72, and 168 h after radiopharmaceutical administration. For 111In-7E11, pharmacokinetic and biodistribution studies were performed at 8, 24, and 72 h. Parallel studies of 177Lu-7E11 in non-tumor-bearing mice at 8, 24, and 72 h post-injection served as controls. Gamma scintigraphy was performed, followed by autoradiography and tissue counting, to demonstrate and quantify the distributions of radioconjugated MAb in the tumor and normal tissues.

Results and Discussion

Both 177Lu- and 111In-7E11 conjugates demonstrated an early blood pool phase in which uptake was dominated by the blood, lung, spleen and liver, followed by uptake and retention of the radiolabeled antibody in the tumor which was most prominent at 24 h. Total accumulation of radioconjugated MAb in tumor at 24 h was greater in the case of 177Lu-7E11 in comparison to that of 111In-7E11. Continued accumulation in tumor was observed for the entire time course studied for both 177Lu-7E11 and 111In-7E11. The liver was the only major organ demonstrating a significant difference in accumulation between the two conjugates. In conclusion, pharmacokinetic and biodistribution studies of 177Lu-7E11 in LNCaP xenograft mouse models support its potential application as a radioimmunotherapeutic agent targeting prostate cancer, and the distribution and tumor uptake of 111In-7E11 appear to be similar to those of 177Lu-7E11, supporting its use as a pre-therapeutic tool to assess the potential accumulation of 177Lu-7E11 radioimmunotherapeutic at sites of prostate cancer. However, the different accumulation patterns of the 111In and 177Lu immunoconjugates in liver will likely prevent the use of 111In-7E11 as a true dosimetry tool for 177Lu-7E11 radioimmunotherapy.

Key words

Prostate cancer Immunoscintigraphy Lutetium-177 Indium-111 Radioimmunotherapy Prostate-specific membrane antigen Bioluminescence imaging 

References

  1. 1.
    Swanson GP, Thompson IM, Basler J (2006) Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer 107:439–450PubMedCrossRefGoogle Scholar
  2. 2.
    Swanson GP, Thompson IM, Basler J (2006) Treatment options in lymph node-positive prostate cancer. Cancer 106:2531–2539PubMedCrossRefGoogle Scholar
  3. 3.
    Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098–1109PubMedCrossRefGoogle Scholar
  4. 4.
    Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23:4591–4601PubMedCrossRefGoogle Scholar
  5. 5.
    Russell PJ, Hewish D, Carter T et al (2004) Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunol Immunother 53:411–421PubMedCrossRefGoogle Scholar
  6. 6.
    Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH (2000) In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60:5237–5243PubMedGoogle Scholar
  7. 7.
    Wright GL Jr, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334PubMedCrossRefGoogle Scholar
  8. 8.
    Fair WR, Israeli RS, Heston WD (1997) Prostate-specific membrane antigen. Prostate 32:140–148PubMedCrossRefGoogle Scholar
  9. 9.
    Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26:5310–5324PubMedCrossRefGoogle Scholar
  10. 10.
    Troyer JK, Beckett ML, Wright GL Jr (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62:552–558PubMedCrossRefGoogle Scholar
  11. 11.
    Troyer JK, Beckett ML, Wright GL Jr (1997) Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30:232–242PubMedCrossRefGoogle Scholar
  12. 12.
    Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927–935PubMedGoogle Scholar
  13. 13.
    Barren RJ 3rd, Holmes EH, Boynton AL, Misrock SL, Murphy GP (1997) Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate 30:65–68PubMedCrossRefGoogle Scholar
  14. 14.
    Elgamal AA, Troychak MJ, Murphy GP (1998) ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 37:261–269PubMedCrossRefGoogle Scholar
  15. 15.
    Feneley MR, Jan H, Granowska M et al (2000) Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer. Prostate Cancer Prostatic Dis 3:47–52PubMedCrossRefGoogle Scholar
  16. 16.
    Tedesco J, Goeckeler W, Becker M, Frank K, Gulyas G, Young S (2005) Development of optimal Lu-177 labeled monoclonal antibody (7E11) construct (CYT-500) for radioimmunotherapy of hormone refractory prostate cancer. J Clin Oncol 23(16S):4765Google Scholar
  17. 17.
    Tedesco J, Wolodzco J, Goeckeler W, Becker M, Hasegawa B, Franc B (2006) Development and characterization of a novel 177Lu-MeO-DOTA-7E11 antibody construct (CYT-500) for the treatment and imaging of prostate adenocarcinoma. AACR Annual MeetingGoogle Scholar
  18. 18.
    Nargund V, Al Hashmi D, Kumar P et al (2005) Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging. BJU Int 95:1232–1236PubMedCrossRefGoogle Scholar
  19. 19.
    Christiansen JJ, Rajasekaran SA, Inge L, Cheng L, Anilkumar G, Bander NH, Rajasekaran AK (2005) N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. Mol Cancer Ther 4:704–714PubMedCrossRefGoogle Scholar
  20. 20.
    Bander NH, Trabulsi EJ, Kostakoglu L et al (2003) Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 170:1717–1721PubMedCrossRefGoogle Scholar
  21. 21.
    Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22:2522–2531PubMedCrossRefGoogle Scholar
  22. 22.
    O'Donoghue JA, Bardies M, Wheldon TE (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36:1902–1909PubMedGoogle Scholar
  23. 23.
    Seo Y, Wong KH, Sun M, Franc BL, Hawkins RA, Hasegawa BH (2005) Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system. J Nucl Med 46:868–877PubMedGoogle Scholar

Copyright information

© Academy of Molecular Imaging 2008

Authors and Affiliations

  • Mei-Hsiu Pan
    • 1
  • Dong-Wei Gao
    • 1
  • Jinjin Feng
    • 1
  • Jiang He
    • 1
  • Youngho Seo
    • 1
  • John Tedesco
    • 2
  • John G. Wolodzko
    • 2
  • Bruce H. Hasegawa
    • 1
  • Benjamin L. Franc
    • 1
  1. 1.Center for Molecular and Functional Imaging, Department of Radiology and Biomedical ImagingUniversity of CaliforniaSan FranciscoUSA
  2. 2.Cytogen CorporationPrincetonUSA

Personalised recommendations